A Study to Investigate the Efficacy, Safety, and Tolerability of AZD4144in Participants With Sepsis-associated Acute Kidney Injury.

Last updated:
2026-08-01
Language and content disclaimer

The content and search results on this site are collected from or provided by third parties. As such some of the information may only be available in the language originally submitted by the sponsor of the trial. Learn more about the information on the search portal.

Linking to Non-Government of Canada Websites

Links to websites not under the control of the Government of Canada, including those to our social media accounts, and to clinical trial records in international registries are provided solely for the convenience of our website visitors. We are not responsible for the accuracy, currency or reliability of the content of such websites. The Government of Canada does not offer any guarantee in that regard and is not responsible for the information found through these links, nor does it endorse the sites and their content.

Visitors should also be aware that information offered by non-Government of Canada sites to which this website links is not subject to the Privacy Act or the Official Languages Act and may not be accessible to persons with disabilities. The information offered may be available only in the language(s) used by the sites in question. With respect to privacy, visitors should research the privacy policies of these non-government websites before providing personal information.

View trial details

Overview

Official protocol title:

A PHASE IIA, RANDOMISED, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTICENTRE STUDY TO ASSESS THE EFFICACY, SAFETY, AND TOLERABILITY OF AZD4144 IN PARTICIPANTS WITH SEPSIS-ASSOCIATED ACUTE KIDNEY INJURY (SERENIA)

Intervention/treatment:
AZD4144
Medical condition:
ACUTE KIDNEY INJURY
Protocol code:
D9440C00004
Control number:
301397
Status:
Recruiting
Approved:
October 01, 2025
Trial phase:
Phase 2
For more information:
ClinicalTrials.gov - NCT07215702
This is an external link. The information is not authorized by the Government of Canada.

Eligibility

Sex: ALL
Age
18 Years to 80 Years
Accepts healthy volunteers: No

Contacts and locations

Contact
Name
AstraZeneca Clinical Study Information Center
Role
CONTACT
Phone:
1-877-240-9479
Sponsor
ASTRAZENECA CANADA INC

Locations

Quebec

Research Site
Lévis, Quebec, G6V 3Z1
Recruiting
Research Site
Montreal, Quebec, H1T 2M4
WITHDRAWN
Research Site
Montreal, Quebec, H2X 3E4
Recruiting
Research Site
Montreal, Quebec, H4J 1C5
Recruiting
Research Site
Québec, Quebec, G1R 2J6
Recruiting
Research Site
Québec, Quebec, G1V 4G5
Not yet recruiting
Did you find what you were looking for?